Compare Cytokinetics Inc (CYTK) vs YieldMax Magnificent 7 Fund of Option Income ETFs (YMAG) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Cytokinetics Inc vs YieldMax Magnificent 7 Fund of Option Income ETFs — how do they compare? Cytokinetics Inc trades at $61.95 (market cap $8.62B), while YieldMax Magnificent 7 Fund of Option Income ETFs trades at $11.43 (market cap $296.92M). The key difference: Cytokinetics Inc is far larger — about 29× YieldMax Magnificent 7 Fund of Option Income ETFs's market cap, and Cytokinetics Inc is more actively traded (2,594,626 versus 1,023,545). Which is the better fit depends on your goals — on Pluang, investors hold Cytokinetics Inc for 19 Days and YieldMax Magnificent 7 Fund of Option Income ETFs for 62 Days on average.
| CYTK | YMAG | |
|---|---|---|
Market Cap | $8.62B | $296.92M |
Volume | 2,594,626 | 1,023,545 |
Sector | Health | Income / Options Overlay |
52-Week High | $87.26 | $15.68 |
52-Week Low | $54.76 | $10.76 |
Typical Hold Time | 19 Days | 62 Days |
Enterprise Value | $8.72B | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Cytokinetics (CYTK) trades at $61.12, down 0.37% on the day, with a bearish technical signal from moving averages despite some oversold RSI readings. The company reported a net loss of $784.96 million on $88.04 million revenue in 2025, with a negative net income margin of -1,321.12% in 2026. Recent news highlights clinical progress for aficamten in hypertrophic cardiomyopathy and executive stock sales.
Wall Street maintains strong bullish sentiment with a 97.14% buy rating and $112.60 consensus price target, but high cash burn, persistent losses, and insider selling pose significant risks. The stock's outlook hinges on successful commercialization of its heart failure pipeline amid substantial financial and competitive pressures.
YMAG trades at $11.49, down 0.69% with a bullish technical signal supported by moving averages. The ETF maintains consistent weekly dividend distributions, though key valuation ratios remain unavailable. Recent news highlights ongoing distribution announcements and trading activity, with the stock showing moderate volatility within a tight $11-12 range.
The outlook remains cautiously optimistic given the bullish technical setup and income generation through dividends. However, risks include NAV stability concerns during earnings periods and dependency on underlying option strategies. Investors should weigh the high distribution yield against potential capital volatility in market downturns.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Cytokinetics Inc
Cytokinetics is a biopharmaceutical company focused on muscle biology. It develops muscle activators and inhibitors as potential treatments for debilitating diseases where muscle performance is compromised or declining.
Read more on CYTK →About YieldMax Magnificent 7 Fund of Option Income ETFs
YMAG is an actively managed 'fund of funds' that provides equal-weighted exposure to the seven YieldMax ETFs tracking the 'Magnificent 7' tech giants (Apple, Microsoft, Alphabet, Amazon, Nvidia, Meta, and Tesla). It seeks to generate high current income by harvesting option premiums across these leaders, offering a streamlined way to access concentrated tech volatility in an income-producing format.
Read more on YMAG →
